Lisata Therapeutics acquires Marea Therapeutics in pipeline pivot toward cardioendocrine drugs
LSTA•Pipeline and funding plans
Proceeds are earmarked to advance MAR001/005 in severe hypertriglyceridemia through Phase 2b, with topline data expected in Q4 2027.
Funding will also support MAR002 in acromegaly, which is entering Phase 2, with topline results also targeted for Q4 2027.
The company projected the financing will fund operations into 2028.
Acquisition and financing announced
Lisata Therapeutics acquired clinical-stage biotech Marea Therapeutics to pivot toward cardioendocrine drug development.
The deal was paired with a private placement of Series C non-voting convertible preferred stock targeting gross proceeds of about $225 million.
